Skip to main content
Clinical Trials/NL-OMON46790
NL-OMON46790
Completed
Not Applicable

A phase 1, open-label, fixed-sequence, drug-drug interaction study between multiple oral doses of Inarigivir Soproxil and a single oral dose of midazolam in healthy subjects - SB-9200/midazolam DDI

Spring Bank Pharmaceuticals, Inc.0 sites16 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Spring Bank Pharmaceuticals, Inc.
Enrollment
16
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Spring Bank Pharmaceuticals, Inc.

Eligibility Criteria

Inclusion Criteria

  • \-Healthy male or female subjects
  • \-18\-55 years, inclusive, at screening
  • \-BMI 18\.0\-30\.0 kg/m2, inclusive, at screening
  • \-Females must be non\-pregnant, non\-lactating and of non childbearing potential

Exclusion Criteria

  • Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1\.5 liters of blood in the 10 months prior the start of this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A phase 1, open-label, fixed-sequence, drug-drug interaction study of APX001 to evaluate the effects of CYP3A4 inhibition and pan-CYP induction in two parallel groups of healthy male and female subjectsFungal infections
NL-OMON47992Amplyx Pharmaceuticals, Inc.36
Completed
Not Applicable
A Phase 1, Drug-Drug Interaction Study to Evaluate the Effect of JBPOS0101 on the Pharmacokinetics of Midazolam and the Interaction between Carbamazepine and JBPOS0101 in Healthy SubjectsDiseases of the nervous system
KCT0008374Bio-Pharm Solutions16
Completed
Not Applicable
A Phase 1, Open-Label, Fixed Sequence Drug-Drug Interaction Study to Assess the Effect of Multiple Doses of Oral THB001 on the Pharmacokinetics of Oral Caffeine, Omeprazole, and Midazolam (CYP1A2, CYP2C19 and CYP3A4 probe substrates) in Healthy Volunteersallergic mediated diseasesallergic asthmaand food allergychronic idiopathic and inducible urticariachronic rhinosinusitis
NL-OMON51382Third Harmonic Bio18
Completed
Not Applicable
A Phase I, open-label, single-sequence drug-drug interaction trial in subjects on stable methadone maintenance therapy, to investigate the potential interaction between TMC278 25 mg q.d. and methadone, at steady-state.AIDSHIV10047438
NL-OMON32622TIBOTEC PHARMACEUTICALS LIMITED, EASTGATE VILLAGE, EASTGATE, LITTLE ISLAND, CO. CORK, IRELAND, In Nederland vertegenwoordigd door Janssen-Cilag B.V. afdeling GCO16
Not yet recruiting
Not Applicable
A phase I, multi-center, open-label, drug-drug interaction study to assess the effect of the CYP1A2 inhibitor, fluvoxamine, on TKI258 (dovitinib) pharmacokinetics in patients with advanced solid tumors.advanced cancersolid tumors10027655
NL-OMON39285ovartis12